Nyxoah (NYXH) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool.

DATE

Thursday, March 19, 2026 at 4:30 p.m. ET

CALL PARTICIPANTS

• Chief Executive Officer — Olivier Taelman
• Chief Financial Officer — John Landry

Need a quote from a Motley Fool analyst? Email pr@fool.com

TAKEAWAYS

• U.S. FDA Approval -- Genio received FDA approval in August, leading to revenue participation from September onward.
• Q4 U.S. Revenue -- $4,500,000 generated, representing initial sales from the commercial launch period.
• U.S. Sales Coverage -- 25 sales representatives focused on 125 of the 400 top hypoglossal nerve stimulation (HGNS) accounts, with expansion to 40 sales reps and 200 accounts in 2026.
• Surgeon and Account Engagement -- 145 surgeons trained across 125 high-volume HGNS accounts; 120 value analysis committee (VAC) submissions with 57 approvals and no rejections reported by year-end.
• U.S. Reimbursement -- Medicare represented 10% and commercial payers 90% of U.S. Genio business; consistent reimbursement achieved with clarity on CMS interim C-code 8011 facility fee set at $31,526 per implant, matching CPT code 64582.
• Gross Revenue -- €6,300,000 in Q4 2025 before €700,000 in revenue deferments, primarily for disposable patches.
• Q4 Net Revenue -- €5,600,000 after deferrals, up from €1,300,000 in the prior year period.
• Q4 U.S. Net Revenue -- Approximately €3,500,000 contributed by U.S. operations in the quarter.
• Q4 Gross Margin -- 64% reported for the quarter.
• 2025 Operating Loss -- €18,600,000 for the year, stable compared to €18,300,000 in 2024 despite increased commercial investment.
• Full-Year Gross Revenue -- €11,000,000 before €1,000,000 in deferrals, compared to €4,500,000 in 2024.
• Full-Year Net Revenue -- €10,000,000 realized, reflecting 122% growth year over year.
• Full-Year Gross Margin -- 63% reported for 2025.
• Full-Year Operating Loss -- €83,500,000, increased from $58,800,000 in 2024 due to U.S. commercialization activities.
• Q4 Cash Position -- €48,000,000 in cash, cash equivalents, and financial assets as of year-end.
• Cash Burn Rate -- CFO Landry stated, "we are looking at approximately €20,000,000 per quarter in the near term," with recent capital raises extending runway into 2027.
• 2026 Guidance -- U.S. net revenue expected to increase 25% sequentially and gross margin projected to rise slightly as sales volume scales; major gross margin step-up anticipated in 2027 with Genio 2.2 patch.
• International Profitability -- Germany identified as the first profitable international market, with other international regions contributing stable revenue.
• Clinical Milestone -- The DREAM pivotal study published, supporting Genio's clinical efficacy and providing differentiation in product labeling.
• Future Label Expansion -- ACCESS study 12-month data expected by July 2026, with a PMA supplement submission planned for label expansion targeting early 2027 approval.

SUMMARY

Nyxoah (NASDAQ:NYXH) reported rapid U.S. commercial uptake of Genio following August FDA approval, with clear progress on sales force expansion, reimbursement, and clinical differentiation confirmed in the transcript. CMS's facility fee alignment and broad commercial payer adoption established uniform reimbursement for Genio, removing pricing uncertainty for new hospital accounts. Management highlighted that revenue growth outpaced prior periods without shelf-loading, attributing adoption to Genio's differentiated design and patient-centric features, and communicating that VAC approvals continue to progress without setbacks. Full-year financial figures indicate significant top-line acceleration driven by the U.S. launch, with investments in U.S. infrastructure linked to operating losses and an ample cash position supporting ongoing U.S. market penetration through 2026 and into 2027.

• Taelman explicitly stated, "there is also no consignment," affirming a sell-through model directly linked to identified implant candidates.
• CFO Landry described, "gross margin to increase slightly over the balance of the year" in 2026, with a "step-function increase" projected in 2027 via next-gen Genio 2.2 patch production.
• The transcript attributes facility fee clarity and patient/surgeon demand to reducing commercial friction for hospital adoption.
• Clinical ACCESS study 12-month result timing and submission pathway for PMA supplement are laid out with the expectation of U.S. label expansion in early 2027.
• The company does not provide precise implant numbers, but direct commentary points to ongoing growth and focus on end-user implantation rather than inventory build-up.

INDUSTRY GLOSSARY

• HGNS: Hypoglossal Nerve Stimulation, a therapy for obstructive sleep apnea involving neurostimulation of the hypoglossal nerve to maintain airway patency.
• VAC: Value Analysis Committee, a hospital body responsible for evaluating and approving new medical devices or therapies for adoption and purchase.
• PMA Supplement: An FDA submission seeking approval for changes or expansions to an already-approved Class III medical device.
• C-code: A temporary code used by CMS for outpatient facility reimbursement of new medical devices or procedures pending assignment of permanent codes.
• CPT code 64582: Current Procedural Terminology code covering implantation of a hypoglossal nerve stimulator device.

Full Conference Call Transcript

Olivier Taelman, Chief Executive Officer, and John Landry, Chief Financial Officer. During the call, we will discuss our operating activities and review our fourth quarter 2025 financial results released after U.S. market close today, after which we will host a question and answer session. The press release can be found on the Investor Relations section of our website. This call is being recorded and will be archived in the Events section on the Investor Relations tab of our website. Before we begin, I would like to remind you that any statements that relate to expectations or predictions of future events, market trends, results, or performance are forward-looking statements. All forward-looking statements are based upon our current estimates and various assumptions.

These forward-looking statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. All forward-looking statements are based upon currently available information, and the company assumes no obligation to update these statements. Accordingly, you should not place undue reliance on these forward-looking statements. For a list and description of the risks and uncertainties associated with our business, please refer to the Risk Factors section of our Form 20-F, which will be filed with the Securities and Exchange Commission. With that, I will now turn the call over to Olivier.

Olivier Taelman: Thank you, Pearson. Good day, everyone, and thank you for joining us for our fourth quarter and full year 2025 earnings call. Let me start with our 2025 key milestones and highlights. 2025 was a transformative year for Nyxoah S.A. We achieved several defining milestones during the year. In early 2025, in anticipation of FDA approval, we hired and trained our U.S. commercial team, including our first 25 sales reps. We developed our strategic launch plan, worked on securing market access, and mapped out target accounts focused on the top 400 highest-volume hypoglossal nerve stimulation (HGNS) accounts around the U.S. On August we received U.S. FDA approval for Genio, followed by actively launching our product.

We secured reimbursement for Genio across both Medicare and commercial payers, resulting already in first implants and revenue as early as September 2025. We successfully executed on our focused launch in the United States. We trained 145 surgeons in 125 high-volume hypoglossal nerve stimulation accounts, of which 57 already received positive value analysis committee approval, resulting in $4,500,000 of revenue generated in Q4. This translates into $720,000 in annualized sales rep productivity during the first full quarter of launch. From a clinical data perspective, the DREAM pivotal study was published in the Journal of Clinical Sleep Medicine. These data demonstrated Genio’s clinical efficacy in both supine and non-supine positions, as reflected in our labeling and differentiating us from competition.

Internationally, we continued driving growth in selected markets, including Germany, United Kingdom, and the Middle East. We closed 2025 with a global gross revenue of €11,000,000 driven by strong Q4 U.S. launch momentum.

Now let me dig in deeper starting with our commercial update. The fourth quarter marked our first full quarter of U.S. commercialization following FDA approval, and we are excited with the first launch results. Let me share with you the key leading indicators that we are tracking. As of 12/31/2025, with 25 sales reps, we focused on 125 out of the top 400 HGNS accounts in the U.S. From these accounts, 145 surgeons were trained. We completed 120 value analysis committee submissions and received 57 approvals already, with no VAC rejections to date. U.S. reimbursement has been consistent for Medicare and many large commercial payers to date.

For the past months, I have had the chance to meet multiple surgeons and sleep customers across the U.S., hearing consistent positive feedback on Genio’s unique approach and the optionality we now offer to patients and physicians. Surgeons are attracted by the bilateral stimulation, the single-incision procedure, and the consistent therapy efficacy across all sleeping positions, which makes Genio unique on the market. In their interactions with patients, they highlight the patient-centric design, including the battery-free implantable, full-body MRI compatibility, and no need for re-surgery due to battery depletion or software upgrades. In addition, sleep physicians note that the first wave of activated patients in the U.S. are providing strong positive feedback on therapy outcomes.

From a reimbursement perspective, ahead of FDA approval, we worked to align Genio coverage with the broad framework of hypoglossal nerve stimulation therapies across both commercial payers and Medicare. I am pleased to report that Genio has been consistently reimbursed by both commercial payers, which represents approximately 90% of our business, and Medicare, which represents the remaining 10% of the Genio business during Q4. Recently, there has been a lot of discussion and communication regarding HGNS reimbursement overall. As is typical for a relatively new product category, in combination with an expanding landscape where Genio enters the market, procedural coding practices continue to mature.

In February 2026, CMS established new interim C-codes for HGNS that facilities will use when billing for traditional Medicare patients, including specific codes 8011, 8012, and 8013, which apply to external power devices including the Genio system. Last Friday, CMS indicated that the new C-code 8011 used for the Genio implant would be reimbursed in the hospital outpatient department at $31,526, in line with 2026 coverage for CPT code 64582. This also means that there is no reimbursement difference between the Genio system and competition. Staying with Medicare, the introduction of C-codes does not change how surgeons bill their physician fee for Medicare procedures. Surgeons are responsible for selecting the appropriate CPT code and potential modifier use.

Given recent CMS guidance, we expect surgeons will elect to use CPT 64582 for their physician fee.

Let us turn now to commercial payers, which represent approximately 90% of our business. Claims continue to be processed under CPT code 64582 or 64568, depending on payer policy, contractual terms, documentation, and individual case review. To date, we have seen strong prior authorization outcomes across cases submitted to commercial payers, including many of the largest in the United States. In conclusion, we view the current reimbursement environment as a normal maturation of an established therapy. With the recent clarity on the facility fee of $31,526 for the Genio C-code, we are confident that it will not have any negative impact on further Genio adoption going forward.

We remain actively engaged with specialty societies and coding authorities to support long-term dedicated HGNS CPT codes.

From an international update perspective, while the U.S. is the primary growth driver, international markets continue to provide a consistent revenue contribution. Our goal is to ensure each of our international markets are profitable, with Germany being the first that has reached this goal. In summary, entering the U.S. market in 2025, which is the largest HGNS market in the world, completes our transition into a commercial organization. The momentum we see in the U.S. launch reinforces our confidence in the opportunity ahead. I will now turn the call over to John for a detailed overview of our financial results.

John Landry: Thank you, Olivier. Starting with the fourth quarter of 2025, gross revenue was €6,300,000 before €700,000 of revenue deferrals, mainly due to disposable patches, which are delivered over time, resulting in net revenue of €5,600,000 compared to €1,300,000 in 2024. This growth was driven by our U.S. commercial launch, which resulted in approximately €3,500,000 of net revenue in the fourth quarter of 2025. Gross margin was 64% in the fourth quarter. Total operating loss for 2025 was €18,600,000 compared to €18,300,000 in 2024. Notably, operating loss remained relatively stable year over year despite significant commercial investments made to support our U.S. commercial launch.

Now let us turn to the full year 2025 results. Gross revenue was €11,000,000 before €1,000,000 of revenue deferrals, mainly due to disposable patches, resulting in net revenue of €10,000,000 compared to €4,500,000 in 2024, or 122% year-over-year growth. Gross margin for the full year of 2025 was 63%. Total operating loss for the full year 2025 was €83,500,000 compared to $58,800,000 in 2024. The increase in total operating loss reflects the acceleration of U.S. commercialization activities in preparation for commercial launch. Our cash position as of 12/31/2025, which includes cash, cash equivalents, and financial assets, totaled €48,000,000. Now as we turn to revenue guidance, we expect U.S. net revenue for 2026 to grow 25% sequentially.

This sequential growth in the U.S. reflects continued surgeon training, additional value analysis committee approvals, and growing surgeon adoption. International revenue is expected to follow typical seasonal patterns. With that, I will now turn the call back to Olivier for closing remarks.

Olivier Taelman: Thank you, John. For 2026, our priority is clear: continue executing on our U.S. commercial launch. To that end, we increased our Salesforce by 15 sales reps and three sales directors in 2026, bringing us to a total of 40 sales reps covering 200 of the top 400 hypoglossal nerve stimulation accounts. During 2026, from a clinical perspective, we are looking forward to seeing our 12-month ACCESS study data on complete concentric collapse and subsequent PMA supplement submission, potentially leading to U.S. label expansion in early 2027. As a fast-growing company, we are expanding our internal manufacturing footprint to further strengthen our competitive position and improve our gross margins.

We expect our 2026 execution to translate into a very strong financial profile as we gain market share in the U.S. Thank you for listening and your continued interest and support for Nyxoah S.A. We will now open for questions.

Operator: Thank you. And as a reminder, to ask a question, you will need to press 11 on your telephone and wait for your name to be announced. To withdraw your question, please press 11 again. Please stand by while we compile the Q&A roster. One moment for our first question. Our first question comes from the line of Adam Maeder from Piper Sandler. Your line is open.

Adam Maeder: Hi. Good afternoon. Thank you for taking the questions, and congrats on the progress. Two questions for me. The first one is just on some of the leading indicators or metrics that you shared, Olivier. If I heard correctly, you have 120 VAC submissions that were made, I think, as of December 31 last year, and I think 57 accounts activated. Can you just kind of help bridge us for the remaining 60 or 63 VAC processes and kind of where those stand, when should we expect more accounts to go active, and just talk about the funnel for new accounts as we move towards that 400 hypoglossal nerve stimulation account target? And then I had a follow-up. Thanks.

Olivier Taelman: Thank you, Adam. So to your point, we have submitted 120 VAC submissions. Already 57 are approved. The other ones will be approved, and we already saw first ones being approved in Q1. As you know, not every hospital has the same timelines when it comes to VAC approvals. But we were extremely pleased to see already the first 57 during Q4. You can expect the remaining to start being approved during Q1, so that is already, I think, answering the first part of your question. The second one is regarding the Salesforce and how many accounts we are covering and how many new accounts we will open going forward.

As I mentioned during my call as well, we already increased our hiring by 15 additional sales reps, so we went from 25 to 40. And with that, on average, each of those 15 will add five new accounts, so that can go up to 75 additional accounts, resulting in 200 out of the 400 high-volume accounts that we will be covering during Q1 and also Q2. I hope this answers your questions.

Adam Maeder: Very helpful, Olivier. Thanks for all the color there. For the follow-up, I guess I am going to ask about complete concentric collapse and the ACCESS study. And if I heard correctly, I think you are targeting early approval in 2027. Maybe just help us understand when we are actually going to see that data presented. I assume that is this year. And if you could just maybe put a finer point on submission timing, I think that is a PMA supplement, but wanted to confirm that. Thank you.

Olivier Taelman: Yes. So yes, it is a PMA supplement that we will be submitting. Now coming back on timing, we have to wait for 12-month data, so by June, we will have 12-month data of all patients. Then we will go into the analysis of the clinical data. That will take up to 30 days. So by July, we should really have a good view on how the data are looking and also use this to prepare the PMA supplement submission. There, we are confronted with regulatory timelines that we cannot really change and influence.

So that is why we calculated more or less one quarter—90 days—once we have submitted all the data, and that is how we end up entering Q1 2027 to obtain the approval. When will we publish the data? This is something we will do as soon as we have our data, so by somewhere July, and then depending on acceptance in the journal, we will definitely publish these data and present them during one of the conferences.

Adam Maeder: Very good. Appreciate all the color. I will jump back in queue. Thank you.

Operator: Thank you, Adam. One moment for our next question. Our next question will come from the line of Jon Block from Stifel. Your line is open.

Jon Block: John, maybe I can just start with you. I mean, obviously, helpful on some of the guidance figures. But any more color you can give us around the cash burn rate, either for Q1 or even on an annual basis when we start thinking about 2026? And then I will just ask a follow-up.

John Landry: Sure, Jon. Thanks for the question. In terms of cash burn, we are looking at approximately €20,000,000 per quarter in the near term. We recall in the fourth quarter, we raised capital vis-à-vis a PIPE as well as convertible debt, which provided us additional cash to get into 2027. So with the capital we have on the balance sheet and the cash burn, which again is €20,000,000 in the near term and will decrease as we gain revenue traction here in the U.S., that will provide us the capital again into 2027.

Jon Block: Okay. Got it. Very helpful. And then let me pivot. Olivier, maybe for you, maybe I could throw a couple questions your way. The first one is, I believe your competitor has been pretty transparent about pursuing their own code and maybe going down that road for 01/01/2028. I think the C-codes bridge you for a little while, but your thoughts on pursuing your own code, what that will entail, and what that may mean. And then can you give us an actual implant number? The number of implants that were done maybe as of the end of the year, or even any color that you are willing to give us into 2026.

Because clearly, of those 57 accounts activated, as you should be, I mean, you are selling into the shelf a little bit when we start thinking about the revenue number. Thanks, guys.

Olivier Taelman: Yes. Thank you, Jon. So yes, when it comes to the reimbursement coding, I am pleased that we see that there is progress made, that there is clarity also now on the facility fee, and that we fully understand what the use of a C-code or an interim C-code means and how it is impacting the business going forward. Yes, also on the fact that we would like to evolve to our own coding, we are following the same pathway forward as competition is doing as well.

And I do think listening carefully and interacting with AMA and also listening carefully to what is going on is that there will be dedicated coding for Genio also in place, most likely somewhere beginning 2028. But in the meantime, the facility fee is clear. We are now waiting for the physician’s fee, although physicians and experts are telling us that they do not expect many differences to how it used to be, meaning using the previous CPT 64582 coding also to calculate the physician fee. So that is one aspect. Second, number of implants. We decided in our leading indicators not to communicate on the precise number of implants.

But on the other hand, I do think it is relatively easy also to get a good estimate when you know that we generated $4,500,000 of revenue in the U.S. in Q4, and you also know what the average price is for the system, being $25,000. So that is also, I think, an easy way forward to get your answer there. But we do not provide clear implant numbers. I hope this answers your question, Jon.

Jon Block: Yeah. I get the math of the ASP and the revenue, and I can do that. But again, some are sitting on the shelf. Right? So you guys were previously giving implants—guess I am trying to just get more granular on how many implants were done, not how many units were sold, of which a subset is sitting on the shelf. But I could follow up with you offline. Thank you.

Olivier Taelman: No. No. But I can—I think it is an important question and topic that you mentioned, and I do not want to avoid this. So first of all, it is clear that we have no policy in putting products on the shelf. We also clearly do not do any consignment. I just want to point out that there is also no consignment. And the way our sales force is operating in the field on business, when we train surgeons and they come with pre-identified patients, once they have these patients, most of the time they are coming with three to five patients.

And based on this, we make sure that we provide them with that number of implants, and we always add one, maximum two implants, depending whether it is three or five cases they have prepared, so that there is some backup in case something would go wrong. I hope to answer your question more clearly in that sense, Jon, because I do think it is important. We are not loading shelves; we are implanting patients.

Jon Block: Got it. Helpful. Thank you.

Operator: Thank you. One moment for our next question. Our next question comes from the line of Suraj Kalia from Oppenheimer. Your line is open.

Suraj Kalia: Hi, Olivier. Can you hear me alright?

Olivier Taelman: Yes. Perfect. Progress.

Suraj Kalia: Hey, Olivier, just wanted to follow up on the previous question so that I get my bearings right. Your competitor's approach—there is some background noise—yeah, there are some police cars driving by. My apologies. So your competitors' approach has been to have a minimum four to five units upfront sale when a new site is added on, and the larger sites, our field checks tell us, you can have 10–12 implants on the shelves. So, Olivier, when you say a new site comes online with, let us say, three identified patients, is your approach also really about four to five unit upfront sales? Really, for that matter, that is the right way to think about it.

And by the same token, Olivier, I am curious how in the high-volume centers, as LivaNova also comes online, do you think this dynamic is sustainable of respective inventory of each player on the shelf? I know it was a long question. Hopefully, you got the gist of it.

Olivier Taelman: Mhmm. Well, I will start by answering the first part. So as I was saying, we treat patients; we do not want to load shelves. I keep insisting on this. And with the example that you used, when we have three patients that are lined up for implants, we are selling four, maximum five devices depending on what the surgeon prefers as a potential backup. That is what we are doing. So we are not additionally selling more devices that are sitting there on the shelf. We are not doing this.

So I do think your calculation and the example were correct: three patients lined up for implant—we sell four, maximum five, just to make sure there is some backup just in case. So that is one aspect. Second thing, you touched on LivaNova. So I was also carefully reading and hearing today’s announcement, and I want to congratulate them on this. But it also means that they are not launching actively currently, but they are waiting till somewhere Q1, if my information is correct, or somewhere beginning 2027 to launch. Now what we do expect if you look a little bit at the technology is that you will have a clear differentiation.

There is Genio—bilateral stimulation, external wearable component, single incision—and then there will be two players with a pacemaker platform that will be more alike and most likely also be considered when it comes back to physicians in making patient choices or selection with which patient will get what. But I feel very confident with our Genio differentiated approach that we can continue also rolling out successfully going forward and that patients also will know what to choose: a single incision with bilateral stimulation versus a pacemaker.

Suraj Kalia: Fair enough. And one follow-up, Olivier. The 57 or so sites that you all have trained, Olivier, admittedly, it is early. But what are you seeing as the key driver for Genio in these sites? Like, what is the key reason that physicians are asking, “Hey, I need this also on the shelves”? And the reason I ask is, look, there has been chatter about men with beards not wanting Genio, so on and so forth. So just give us an idea about what you are seeing in the field to set the stage for market share approximations. Least between the two current players. Gentlemen, thank you for taking my questions.

Olivier Taelman: You, Suraj. So maybe starting by clarifying something. We have trained more than 57 accounts in the U.S. Just to be very clear about this, we have already 145 surgeons, and they represent or they are active in 120 accounts of the 125 high-volume accounts that we are targeting. So we have trained in 120 accounts. The 57 number is the number where we already have a full approval, where the VAC is approved, and where we actively were doing business during Q4. Just to clarify this one. Then answering the question on why surgeons are choosing Genio, I think you can summarize it in three major buckets.

First, there is the optionality that we are providing by breaking the monopoly that was existing, and not all patients like or accept a pacemaker. Second, there is the Genio differentiation: a clear single-incision implant technique—something that resonates extremely well with surgeons to have a single incision compared to multiple incisions. And then last, for the surgeon, also the bilateral stimulation and the related quality of airway opening with a beautiful tongue protrusion. This is something that we are hearing back constantly, also with staying efficient in complex airway obstructions. So those are the three things. I hope this answers your question.

Operator: Yes. Thank you. Once again, 11 for questions. Our next question will come from the line of David Rescott from Baird. Your line is open.

Tommy Hahn: Great. Good afternoon, guys, and thanks for the question. This is Tommy Hahn on for Dave. I was wondering if you guys would like to put a finer point on your assumptions in guidance around new account adds versus increasing utilization in your existing accounts relative to the Q4 exit rate?

Olivier Taelman: So as I was mentioning, we have a focused approach with the 25 salespeople. Starting immediately post FDA approval, we were able to reach 125 out of the 400 high volume. Today, we added 15 reps, so now we are already reaching out to 200 of the 400 accounts. Next to this, we have already trained 145 surgeons. We have surgeons lined up for training. There were even waiting lists. So we are doing trainings almost every weekend across the U.S., and we will also significantly increase the number of accounts where we can do business and we can implant patients. So that can go up all the way to 200.

In the meantime, of course, there is each time a VAC submission that takes place. It is depending a little bit account by account how fast it can go. We see that it can happen sometimes in two weeks, sometimes it takes a month, sometimes even longer. But what you can expect in gradually scaling up is that over time—and when I define over time, by the end of Q1—we should be covering all the way up to potentially 220 accounts where we are present.

Tommy Hahn: Great. Thank you. And I was wondering if you guys wanted to provide a little bit more color around OpEx guidance and gross margin guidance for 2026 and what the drivers are behind that. And separately, maybe for procedures performed so far, can you help us understand where those patients are coming from? Is it those who were expecting to get another HGNS device or more so people who had been waiting on the sidelines? Thank you.

Olivier Taelman: Yes. So I will take the last part of the question and the first part I will hand over to John. So the last part—where our patients are coming from—it is clear that in those high-volume accounts, there are well-established referral networks, and we see patients being referred the moment that they arrive with the surgeon. So today, with Genio, there is optionality. Patients are proposed both technologies, and we see that a high number of these patients are choosing Genio for the reasons I mentioned from a surgeon perspective. But when it comes to patients, what is driving them is that, in fact, Genio is designed so patients can forget they even have an implant.

It is a very minimally invasive surgery, and it is also designed to evolve with patients. As example, upgradable software, an intuitive patient app, no need for a re-surgery. So that is where we see a lot of patients being very appealed when they once are confronted and being proposed and explained what Genio can do. So that is one aspect. Going forward, it is also clear that we are establishing strong relationships with sleep physicians and that we are also working on referring our own Genio patients. And, John, with that, maybe on the gross margin.

John Landry: For the questions there, Tommy, on the model. In regards to gross margin, I would expect gross margin to increase slightly over the balance of the year, really due to increased sales volume and being able to spread the overhead over more units. So you will see a slight increase in 2026 as we move through the year. The major step-function increase in gross margin that you can expect to see is probably more in early 2027 when we launch our next-generation disposable patch activation chip, or Genio 2.2 specifically. That will allow us to have an enhanced patient experience plus also allow us to significantly reduce the cost of the disposable patch going forward.

So the next step-function up, into, say, the 70% range, will come in 2027. In terms of OpEx, we do not provide specific OpEx numbers in terms of guidance, but let me give you some color to provide some direction. In terms of our R&D expense, which includes things like quality, regulatory, medical affairs, clinical, in addition to the true R&D spend, what you can expect to see there is that number to go down over the course of 2026 sequentially on a quarterly basis, as some of the investments that we made in 2025 getting ready for commercialization will start to fall off over the course of 2026.

In regards to SG&A, the main driver there, Tommy, is really around U.S. sales expansion. So as Olivier mentioned, we expanded by 15 sales reps in 2026 in the first quarter. So you can expect our Q3–Q4 run rate to increase due to the increase of these 15 sales reps as well as their three respective sales directors. So that would be the major investments we make in the SG&A sphere this year. All the other infrastructure investments, we are going to leverage those as we built those out in 2025. So hopefully that is helpful as you think about the model, and that is where we are looking at for 2026.

Tommy Hahn: Yep. Very helpful. Thanks for the color.

Operator: You are welcome. Thank you. I am not showing any further questions at this time. With that, this concludes the question and answer session. Thank you for your participation in today's conference. This does conclude the program. You may now disconnect. Everyone, have a great day.

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. Parts of this article were created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.